Clinical Trials
11 trialsNCT06638931 2026-04-15
ANTARES
Instituto do Cancer do Estado de São Paulo
Phase 2 Recruiting
NCT04081701 2025-11-21
DOMINO-START
Weill Medical College of Cornell University
Phase 4 Recruiting
NCT07167329 2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2 Recruiting
NCT00330564 2024-06-27
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05424016 2023-12-13
PRO-HEB
Assistance Publique - Hôpitaux de Paris
Phase NA Recruiting
NCT02120040 2023-04-06
PsychoVHL
Assistance Publique Hopitaux De Marseille
Phase NA Completed
NCT02108002 2018-09-14
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only)
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00052013 2017-03-06
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584
Novartis
Phase 2 Completed
NCT01266070 2017-02-13
TKI 258 in Von Hippel-Lindau Syndrome (VHL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00589784 2016-01-25
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT01015300 2012-05-11
Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease
Dartmouth-Hitchcock Medical Center
Phase EARLY_PHASE1 Terminated